Abstract Number: 133 • 2016 ACR/ARHP Annual Meeting
Agreement Between DAS28-ESR, DAS28-CRP, SDAI, CDAI (Simplified/Clinical Disease Activity Index), ACR/EULAR Remission Criteria and Ultrasound Scoring (Naredo-12) in Patients with Rheumatoid Arthritis in Routine Care
Background/Purpose: Clinical remission is now a realistic goal in managing rheumatoid arthritis (RA) with treat to target strategy assessed according to different composite scores (DAS28,…Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…Abstract Number: 546 • 2016 ACR/ARHP Annual Meeting
Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates
Background/Purpose: Patient global assessment (PtGA), despite not being exclusively related to disease activity, is included in Boolean-based remission (BR) criteria for RA. This study evaluated…Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting
Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study
Background/Purpose: The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…Abstract Number: 1974 • 2016 ACR/ARHP Annual Meeting
Is Ultrasound of the Hands Enough to Reveal Ongoing Subclinical Inflammation in Rheumatoid Arthritis Patients in Clinical Remission According to Composite Scores?
Background/Purpose: Several studies have shown the presence of subclinical inflammation by ultrasound (US) in rheumatoid arthritis (RA) patients despite clinical remission according to clinical composite…Abstract Number: 2487 • 2016 ACR/ARHP Annual Meeting
In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
Background/Purpose: Ultrasound (US) detected synovitis predicts flare in patients with rheumatoid arthritis (RA), while the role of tenosynovitis has yet to be established. The aim…Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting
The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting
Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden
Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting
Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?
Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting
Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen
Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…Abstract Number: 431 • 2015 ACR/ARHP Annual Meeting
Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission
Background/Purpose: To compare physicians' opinion on and adherence to treatment study protocols targeted at either Disease Activity Score (DAS) ≤2.4 or <1.6. Methods: The BeSt…Abstract Number: 436 • 2015 ACR/ARHP Annual Meeting
Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?
Background/Purpose: At the present time remission is the target for treatment of rheumatoid arthritis (RA). Various composite indices are available that can be used to…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »